China Losartan Potassium Prices Expected to Stay Balanced on Improved Availability

China’s Losartan Potassium (USP) FOB Zhejiang market is expected to remain broadly stable to slightly softer in the second half of August 2026, following a 1.28% month-on-month increase in July. The August market is being shaped by higher inventories, which have reduced immediate procurement urgency after tighter prompt availability in July. However, firm raw-material costs and continued export demand are expected to limit the downside and provide a floor to Losartan Potassium offers.

In July, Losartan Potassium prices firmed as exporters absorbed a larger share of production and prompt availability tightened. Zhejiang Huahai’s mid-July disclosure of more than 35% growth in first-half overseas API sales highlighted strong export off-take, particularly from the US and Brazil. Domestic pharmaceutical demand remained moderately supportive, while formulators and generic-drug manufacturers accepted higher offers to secure deliveries. Supply was also affected by producers directing tetrazole and biphenyl intermediates toward higher-margin sartan production, while elevated imidazole-based intermediate costs increased manufacturing expenses. Despite this, no major outages were reported across the Zhejiang-Jiangsu API corridor.

During the first half of August, Losartan Potassium prices stabilized as inventories increased following the tighter supply conditions observed in July. Improved availability reduced the urgency among buyers and encouraged more cautious procurement, preventing exporters from sustaining the earlier price momentum. Production remained accessible, while normalized logistics through major eastern Chinese ports provided additional supply flexibility. Consequently, Losartan Potassium market sentiment shifted from July’s firmer tone toward a more balanced position, with sellers facing greater resistance to further price increases.

For the second half of August, Losartan Potassium prices are anticipated to remain under moderate downward pressure as inventory availability continues to improve and buyers maintain disciplined purchasing. The expected correction is likely to remain limited, however, as production costs for imidazole- and tetrazole-based intermediates remain elevated. Export demand from major pharmaceutical markets will also remain an important support factor, particularly if overseas buyers begin rebuilding inventories for Losartan Potassium ahead of the year-end procurement cycle.

Looking ahead, ChemAnalyst expects Losartan Potassium prices to experience a short-lived, inventory-led correction through August and September before gradually strengthening toward late Q4. Pre-year-end restocking, holiday-related shipping reductions, and sustained raw-material cost pressure could tighten availability from October onward, with stronger constriction anticipated around December and January. Any renewed increase in export demand for Losartan Potassium, changes in intermediate allocation, or unexpected logistics disruptions could accelerate the recovery. Overall, the second-half August market is expected to remain balanced, with higher inventories restraining upside while production-cost pressures prevent a significant decline.